Therapeutic potential of implanted tissue-engineered bioartificial muscles delivering recombinant proteins to the sheep heart

Annals of the New York Academy of Sciences

Volumn 961, Issue , 2002, Pages 78-82

  Lu, Y ^a   Shansky, J ^b   Del Tatto, M ^a,b   Ferland, P ^b   Mcguire, S ^b   Marszalkowski, J ^b   Maish, M ^a   Hopkins, R ^a   Wang, X ^a,b   Kosnik, P ^b   Nackman, M ^b   Lee, A ^b   Creswick, B ^a,b   Vandenburgh, H ^a,b,c  

^a BROWN UNIVERSITY   (United States)

^b Cell Based Delivery Inc   (United States)

^c c/o Cell Based Delivery Inc ^*  (United States)

Author keywords

Angiogenesis; Gene therapy; Ischemic heart disease; Tissue engineering

Indexed keywords

RECOMBINANT PROTEIN; RECOMBINANT SOMATOMEDIN C; RECOMBINANT VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; BIOARTIFICIAL ORGAN; CONFERENCE PAPER; CONTROLLED STUDY; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HEART; HISTOCHEMISTRY; IMPLANTATION; MUSCLE TRANSPLANTATION; MYOBLAST; NONHUMAN; SHEEP; TISSUE ENGINEERING; VASTUS LATERALIS MUSCLE; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE;

ANIMALIA; OVIS ARIES;

EID: 0036289540     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb03055.x     Document Type: Conference Paper

References (3)

1. Gene transfer for angiogenesis in coronary artery disease
2. Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure
3. Recombinant vascular endothelial growth factor secreted from tissue-engineered bioartificial muscles promotes localized angiogenesis